Company / Shareholders' Equity
ARS Pharmaceuticals, Inc. Shareholders' Equity History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$114.3M
FY2025
5-year range
-$31.3M / $256.8M
FY2021-FY2025
Trend
-55.5%
vs FY2024
Sector context
#168 of 213
Health Care
What the data says
ARS Pharmaceuticals, Inc.'s shareholders' equity of $114M is lower than 79% of companies in the Health Care sector (FY2025). Declined from $231M to $114M over the past 2 years.
Based on SEC 10-K filings.
$114M in FY2025.
Declined from $231M to $114M over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 21% in Health CareTop 79% of 213This company $114.3M Sector average $2.5B
▼
-95.5% below sector average
Key checks
Key Insights
- In FY2025, shareholders' equity decreased 55.5% year-over-year.
- Ranks #168 out of 213 companies in the Health Care sector.
- Peak shareholders' equity was recorded in FY2024.
- Lowest shareholders' equity in the period was in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -1.44 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $114.3M | -55.5% |
| FY2024 | $256.8M | +11.3% |
| FY2023 | $230.8M | +838.0% |
| FY2022 | -$31.3M | +0.0% |
| FY2021 | -$31.3M | -122.5% |
| FY2020 | -$14.1M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026